Phase 2 Trial of Neuren’s NNZ-2591 Cleared to Start in US, Australia

Phase 2 Trial of Neuren’s NNZ-2591 Cleared to Start in US, Australia

322607

Phase 2 Trial of Neuren’s NNZ-2591 Cleared to Start in US, Australia

Neuren Pharmaceuticals has received regulatory approval in the U.S. and Australia to start its Phase 2 trial of NNZ-2591, an investigational therapy for Angelman syndrome. The study (NCT05011851), which is not yet recruiting, will include up to 20 children, ages 3 to 17, with a confirmed diagnosis of Angelman syndrome. Trial results are expected in early 2023. With the Human Research Ethics Committee’s approval in Australia, Neuren can initiate clinical testing in Queensland Children’s Hospital/Centre…

You must be logged in to read/download the full post.